Mirum Pharmaceuticals (NASDAQ:MIRM – Free Report) had its price target reduced by Raymond James from $84.00 to $77.00 in a report released on Wednesday, Benzinga reports. Raymond James currently has a strong-buy rating on the stock. A number of other research analysts also recently commented on the stock. Robert W. Baird raised their target price […]
JMP Securities reissued their market outperform rating on shares of Mirum Pharmaceuticals (NASDAQ:MIRM – Free Report) in a report published on Monday morning, Benzinga reports. JMP Securities currently has a $70.00 price objective on the stock. Other research analysts have also recently issued research reports about the company. Robert W. Baird raised their price target […]
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report)’s share price gapped up prior to trading on Wednesday . The stock had previously closed at $31.00, but opened at $32.28. Mirum Pharmaceuticals shares last traded at $32.35, with a volume of 70,778 shares changing hands. Analyst Upgrades and Downgrades Several equities analysts recently commented on MIRM […]
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) CFO Eric Bjerkholt bought 10,000 shares of the firm’s stock in a transaction dated Monday, September 11th. The shares were acquired at an average price of $29.65 per share, for a total transaction of $296,500.00. Following the acquisition, the chief financial officer now directly owns 10,000 shares […]
HC Wainwright reaffirmed their buy rating on shares of Mirum Pharmaceuticals (NASDAQ:MIRM – Free Report) in a report released on Friday morning, Benzinga reports. They currently have a $63.00 price objective on the stock. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q2 2024 earnings at $0.23 EPS, Q3 2024 earnings at $0.38 EPS, Q4 […]